CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

European Journal of Pharmacology

Volumn 769, Issue , 2015, Pages 266-273

  Arai, Kiyoshi ^a   Tsuruoka, Hiroyuki ^a   Homma, Tsuyoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Aldosterone; CS 3150; Mineralocorticoid receptor antagonist; Renal injury; Salt sensitive hypertension

Indexed keywords

1 (2 HYDROXYETHYL) 4 METHYL N [4 (METHYLSULFONYL)PHENYL] 5 [2 (TRIFLUOROMETHYL)PHENYL] 1H PYRROLE 3 CARBOXAMIDE; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; EPLERENONE; PROTECTIVE AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG; CS-3150; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM; PYRROLE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIORENAL INJURY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; GLOMERULOSCLEROSIS; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TUBULE DAMAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; BLOOD PRESSURE; CELL PROTECTION; DAHL RAT; DRUG EFFECTS; HEART; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SAFETY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYTOPROTECTION; HEART; HYPERTENSION; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; POTASSIUM; PYRROLES; RATS; RATS, INBRED DAHL; RECEPTORS, MINERALOCORTICOID; SAFETY; SULFONES;

EID: 84948951465     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.11.028     Document Type: Article

References (45)

1. C. Anton, A.R. Cox, R.D. Watson, and R.E. Ferner The safety of spironolactone treatment in patients with heart failure J. Clin. Pharm. Ther. 28 2003 285 287
2. K. Arai, T. Homma, Y. Morikawa, N. Ubukata, H. Tsuruoka, K. Aoki, H. Ishikawa, M. Mizuno, and T. Sada Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist Eur. J. Pharmacol. 761 2015 226 234
3. O. Baltatu, C. Cayla, R. Iliescu, D. Andreev, C. Jordan, and M. Bader Abolition of hypertension-induced end-organ damage by androgen receptor blockade in transgenic rats harboring the mouse ren-2 gene J. Am. Soc. Nephrol. 13 2002 2681 2687
4. M.A. Bayorh, G. Mann, M. Walton, and D. Eatman Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats Clin. Exp. Hypertens. 28 2006 121 132
5. S.J. Buss, J. Backs, M.M. Kreusser, S.E. Hardt, C. Maser-Gluth, H.A. Katus, and M. Haass Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats Endocrinology 147 2006 2526 2534
6. D.A. Calhoun, and W.B. White Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension J. Am. Soc. Hypertens. 2 2008 462 468
7. N. Chapman, J. Dobson, S. Wilson, B. Dahlöf, P.S. Sever, H. Wedel, and N.R. Poulter Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 2007 839 845
8. A. Chrysostomou, and G. Becker Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease New Engl. J. Med. 345 2001 925 926
9. C.S. Cook, L. Zhang, G.B. Ames, J. Fischer, J. Zhang, and S. Levin Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats Xenobiotica 33 2003 305 321
10. M. de Gasparo, S.E. Whitebread, G. Preiswerk, X. Jeunemaître, P. Corvol, and J. Ménard Antialdosterones: incidence and prevention of sexual side effects J. Steroid Biochem. 32 1989 223 227
11. D.R. Feller, and M.C. Gerald Stimulation of liver microsomal drug metabolism in male and female mice by spironolactone and aldadiene Proc. Soc. Exp. Biol. Med. 136 1971 1347 1350
12. A. Fiebeler, D.N. Muller, E. Shagdarsuren, and F.C. Luft Aldosterone, mineralocorticoid receptors, and vascular inflammation Curr. Opin. Nephrol. Hypertens. 16 2007 134 142
13. J.W. Funder Mineralocorticoid receptor activation and oxidative stress Hypertension 50 2007 840 841
14. N.H. García, S.T. Baigorria, and L.I. Juncos Hyperkalemia, renal failure, and converting-enzyme inhibition: an overrated connection Hypertension 38 2001 639 644
15. A. Iyer, V. Chan, and L. Brown The DOCA-salt hypertensive rat as a model of cardiovascular oxidative and inflammatory stress Curr. Cardiol. Rev. 6 2010 291 297
16. A. Karim Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability Drug Metab. Rev. 8 1978 151 188
17. A.M. Kaukonen, H. Lennernäs, and J.P. Mannermaa Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats J. Pharm. Pharmacol. 50 1998 611 619
18. J.P. Knochel, and M.G. White The role of aldosterone in renal physiology Arch. Intern. Med. 131 1973 876 884
19. P. Kolkhof, M. Delbeck, A. Kretschmer, W. Steinke, E. Hartmann, L. Bärfacker, F. Eitner, B. Albrecht-Küpper, and S. Schäfer Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury J. Cardiovasc. Pharmacol. 64 2014 69 78
20. C.A. LaLone, D.L. Villeneuve, J.E. Cavallin, M.D. Kahl, E.J. Durhan, E.A. Makynen, K.M. Jensen, K.E. Stevens, M.N. Severson, C.A. Blanksma, K.M. Flynn, P.C. Hartig, J.S. Woodard, J.P. Berninger, T.J. Norberg-King, R.D. Johnson, and G.T. Ankley Cross-species sensitivity to a novel androgen receptor agonist of potential environmental concern, spironolactone Environ. Toxicol. Chem. 32 2013 2528 2541
21. S.H. Lee, T.H. Yoo, B.Y. Nam, D.K. Kim, J.J. Li, D.S. Jung, S.J. Kwak, D.R. Ryu, S.H. Han, J.E. Lee, S.J. Moon, D.S. Han, and S.W. Kang Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions Am. J. Physiol. Ren. Physiol. 297 2009 F1381 F1390
22. P. Lijnen, and V. Petrov Induction of cardiac fibrosis by aldosterone J. Mol. Cell. Cardiol. 32 2000 865 879
23. L.C. Liu, E. Schutte, R.T. Gansevoort, P. van der Meer, and A.A. Voors Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease Expert Opin. Investig. Drugs 24 2015 1123 1135
24. H. Matsui, K. Ando, H. Kawarazaki, A. Nagae, M. Fujita, T. Shimosawa, M. Nagase, and T. Fujita Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder Hypertension 52 2008 287 294
25. T.A. Mavrakanas, K. Gariani, and P.Y. Martin Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review Eur. J. Intern. Med. 25 2013 173 176
26. K. Nagata, K. Obata, J. Xu, S. Ichihara, A. Noda, H. Kimata, T. Kato, H. Izawa, T. Murohara, and M. Yokota Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats Hypertension 47 2006 656 664
27. T. Nariai, K. Fujita, M. Mori, S. Katayama, S. Hori, and K. Matsui SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats J. Cardiovasc. Pharmacol. 59 2012 458 464
28. T. Nariai, K. Fujita, K. Kawane, M. Mori, R. Nakayama, K. Matsuda, S. Katayama, N. Fukuda, S. Hori, M. Iwata, F. Hasegawa, K. Suzuki, and H. Kato DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats J. Pharmacol. Exp. Ther. 354 2015 2 9
29. A. Nishiyama, and Y. Abe Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade J. Pharmacol. Sci. 100 2006 9 16
30. T. Ohtani, M. Ohta, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, Y. Takeda, J. Yoshida, T. Miwa, M. Okamoto, T. Masuyama, Y. Nonaka, and M. Hori Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 2007 R946 R954
31. B.F. Palmer Proteinuria as a therapeutic target in patients with chronic kidney disease Am. J. Nephrol. 27 2007 287 293
32. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction New Engl. J. Med. 348 2003 1309 1321
33. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators New Engl. J. Med. 341 1999 709 717
34. J.P. Rapp, S.Y. Tan, and H.S. Margolius Plasma mineralocorticoids, plasma renin, and urinary kallikrein in salt-sensitive and salt-resistant rats Endocr. Res. Commun. 5 1978 35 41
35. R. Rocha, P.N. Chander, K. Khanna, A. Zuckerman, and C.T. Stier Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats Hypertension 31 1998 451 458
36. D.A. Sica Eplerenone: a new aldosterone receptor antagonist - are the FDAs restrictions appropriate? J. Clin. Hypertens. (Greenwich) 4 2002 441 445
37. D.A. Sica Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis Heart Fail. Rev. 10 2005 23 29
38. S. Stefani, G.L. Aguiari, A. Bozza, I. Maestri, E. Magri, P. Cavazzini, R. Piva, and L. del Senno Androgen responsiveness and androgen receptor gene expression in human kidney cells in continuous culture Biochem. Mol. Biol. Int. 32 1994 597 604
39. Y. Takeda Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension Hypertens. Res. 32 2009 321 324
40. Y. Terada, T. Kobayashi, H. Kuwana, H. Tanaka, S. Inoshita, M. Kuwahara, and S. Sasaki Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A J. Am. Soc. Nephrol. 16 2005 2296 2305
41. N. Tsuboi, T. Kawamura, H. Okonogi, T. Ishii, and T. Hosoya The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease J. Renin Angiotensin Aldosterone Syst. 13 2012 113 117
42. Y. Uehara, Y. Kawabata, H. Shirahase, K. Wada, Y. Hashizume, S. Morishita, A. Numabe, J. Iwai, H. Matsuoka, and T. Sugimoto Radical scavenging properties of indapamide and renal protection in Dahl salt-sensitive rats Hypertens. Res. 15 1992 17 26
43. D. Verzola, M.T. Gandolfo, F. Salvatore, B. Villaggio, F. Gianiorio, P. Traverso, G. Deferrari, and G. Garibotto Testosterone promotes apoptotic damage in human renal tubular cells Kidney Int. 65 2004 1252 1261
44. M.H. Weinberger, B. Roniker, S.L. Krause, and R.J. Weiss Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am. J. Hypertens. 15 2002 709 716
45. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, B. Pitt, and EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms New Engl. J. Med. 364 2011 11 21